Drug General Information (ID: DDIVUWASRI)
  Drug Name Cladribine Drug Info Durvalumab Drug Info
  Drug Type Small molecule Monoclonal antibody
  Therapeutic Class Antineoplastics Antineoplastics

 Mechanism of Cladribine-Durvalumab Interaction (Severity Level: Major)
     Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Cladribine Durvalumab
      Mechanism Immunosuppressive effects Immunosuppressive effects
      Key Mechanism Factor 1
Factor Name Immunosuppressive effects
Factor Description Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
      Mechanism Description
  • Additive immunosuppressive effects by the combination of Cladribine and Durvalumab 

Recommended Action
      Management Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.

References
1 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2 Product Information. Leustatin (cladribine). Ortho Biotech Inc, Raritan, NJ.